Reaction
Pulpitis Dental reporting signals
As of the last recalculation, Pulpitis Dental appears in 913 FAERS reports alongside 13 co-occurring drug terms. The strongest observed disproportionality signal is FONDAPARINUX SODIUM (PRR 42.9).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Fondaparinux Sodium | 15 | 42.9 | 43.0 |
| Granisetron Hydrochloride | 18 | 40.1 | 40.1 |
| Mesna | 10 | 27.4 | 27.4 |
| Chlorhexidine Gluconate | 10 | 25.2 | 25.2 |
| Ribociclib | 31 | 23.1 | 23.2 |
| Candesartan | 33 | 21.8 | 21.9 |
| Granisetron | 9 | 19.7 | 19.8 |
| Buprenorphine Hydrochloride, Naloxone Hydrochloride | 18 | 17.3 | 17.3 |
| Encorafenib | 6 | 13.9 | 13.9 |
| Mesna Injection | 5 | 13.9 | 13.9 |
| Ocrelizumab | 36 | 13.7 | 13.7 |
| Denosumab | 86 | 10.6 | 10.6 |
| Adapalene | 3 | 0.4 | 0.4 |